Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial in Platinum-refractory Ovarian Cancer: A Randomized Multicenter Trial With SU11248 to Evaluate Dosage, Tolerability, Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor Monotherapy

NCT00543049 is registered in ClinicalTrials.gov with AGO Study Group as lead sponsor.

NCT NCT00543049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00543049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial in Platinum-refractory Ovarian Cancer: A Randomized Multicenter Trial With SU11248 to Evaluate Dosage, Tolerability, Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor Monotherapy
Lead sponsor
AGO Study Group
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
Not reported
Enrollment
73 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the fallopian tube, platinum refractory epithelial ovarian cancer, primary cancer of the peritoneum